Trial Profile
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal Function
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2022
Price :
$35
*
At a glance
- Drugs Pemafibrate (Primary) ; Fenofibrate
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Kowa Pharmaceutical; Kowa Research Institute
- 01 Oct 2019 Status changed from active, no longer recruiting to completed.
- 21 Jul 2019 This trial has been completed in Hungary and Bulgaria (End Date: 24 Jun 2019), according to European Clinical Trials Database.
- 17 Dec 2018 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.